These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 8502592)

  • 1. [Test with calcitonin as an index of parathyroid function in chronic renal failure].
    Matuszkiewicz-Rowińska J; Niemczyk S; Bogdańska-Straszyńska B; Ostrowski K
    Pol Arch Med Wewn; 1993 Feb; 89(2):102-6. PubMed ID: 8502592
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Effect of salmon calcitonin on bone mineral density and calcium-phosphate metabolism in chronic hemodialysis patients with secondary hyperparathyroidism].
    Matuszkiewicz-Rowińska J; Niemczyk S; Przedlacki J; Puka J; Switalski M; Ostrowski K
    Pol Arch Med Wewn; 2004 Jul; 112(1):797-803. PubMed ID: 15526839
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Calcitonin-induced hypocalcaemia as a possible index of osteoclastic activity in patients with chronic renal failure.
    Del Río A; Rico H; Bordiu E; Novoa D
    Nephron; 1987; 47(4):241-5. PubMed ID: 3696325
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Close association between parathyroid hormone and left ventricular function and structure in end-stage renal failure patients under maintenance hemodialysis.
    Nasri H; Baradaran A
    J Ayub Med Coll Abbottabad; 2004; 16(2):3-8. PubMed ID: 15455608
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Close association between parathyroid hormone and left ventricular function and structure in end-stage renal failure patients under maintenance hemodialysis.
    Nasri H; Baradaran A; Naderi AS
    Acta Med Austriaca; 2004 Aug; 31(3):67-72. PubMed ID: 15515479
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The calcitonin-calcium relation curve and calcitonin secretory parameters in renal patients with variable degrees of renal function.
    Messa P; Mioni G; Turrin D; Guerra UP
    Nephrol Dial Transplant; 1995 Dec; 10(12):2259-65. PubMed ID: 8808222
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factors modulating cytosolic calcium. Role in lipid metabolism and cardiovascular morbidity and mortality in peritoneal dialysis patients.
    Gadallah MF; el-Shahawy M; Andrews G; Ibrahim M; Ramdeen G; Hanna D; Gorospe W; Morkos A; Abbassian M; Moles K
    Adv Perit Dial; 2001; 17():29-36. PubMed ID: 11510292
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of CAPD and hemodialysis on parathyroid function.
    Malberti F; Corradi B; Imbasciati E
    Adv Perit Dial; 1996; 12():239-44. PubMed ID: 8865912
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Evaluation of the treatment efficacy of secondary hyperparathyroidism with oral pulse doses of alphacalcidol].
    Switalski M; Kuriga M; Wańkowicz Z
    Pol Arch Med Wewn; 1997 Oct; 98(10):358-65. PubMed ID: 9557090
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Insulin-like growth factor system components in hyperparathyroidism and renal osteodystrophy.
    Jehle PM; Ostertag A; Schulten K; Schulz W; Jehle DR; Stracke S; Fiedler R; Deuber HJ; Keller F; Boehm BO; Baylink DJ; Mohan S
    Kidney Int; 2000 Feb; 57(2):423-36. PubMed ID: 10652019
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A calcimimetic agent acutely suppresses parathyroid hormone levels in patients with chronic renal failure. Rapid communication.
    Antonsen JE; Sherrard DJ; Andress DL
    Kidney Int; 1998 Jan; 53(1):223-7. PubMed ID: 9453023
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A long-term, multicenter study of the efficacy and safety of paricalcitol in end-stage renal disease.
    Lindberg J; Martin KJ; González EA; Acchiardo SR; Valdin JR; Soltanek C
    Clin Nephrol; 2001 Oct; 56(4):315-23. PubMed ID: 11680662
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of cinacalcet on bone remodeling and renal function in transplant patients with persistent hyperparathyroidism.
    Schwarz A; Merkel S; Leitolf H; Haller H
    Transplantation; 2011 Mar; 91(5):560-5. PubMed ID: 21192318
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Long-term treatment with large doses of alphacalicidol in secondary hyperparathyroidism of patients dialyzed for end stage renal failure].
    Matuszkiewicz-Rowińska J; Niemczyk S; Pacocha E; Puka J; Switalski M; Bogdańska-Straszyńska B; Ostrowski K
    Pol Arch Med Wewn; 1996 Jul; 96(1):15-22. PubMed ID: 8966141
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Changes in serum calcium concentration following eel calcitonin analogue administration as an index of osteoclastic bone resorption in patients with secondary hyperparathyroidism].
    Kato N
    Nihon Jinzo Gakkai Shi; 1995 May; 37(5):291-9. PubMed ID: 7609328
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect Modifying Role of Serum Calcium on Mortality-Predictability of PTH and Alkaline Phosphatase in Hemodialysis Patients: An Investigation Using Data from the Taiwan Renal Registry Data System from 2005 to 2012.
    Lin YC; Lin YC; Hsu CY; Kao CC; Chang FC; Chen TW; Chen HH; Hsu CC; Wu MS;
    PLoS One; 2015; 10(6):e0129737. PubMed ID: 26107510
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intact parathyroid hormone, ionized calcium and calcium infusion test in the evaluation of hyperparathyroidism in chronic renal failure.
    Pietilä K; Mörsky P; Pasternack A; Mustonen J; Koivula T
    Nephron; 1987; 47(4):284-9. PubMed ID: 3696331
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A calcimimetic agent lowers plasma parathyroid hormone levels in patients with secondary hyperparathyroidism.
    Goodman WG; Frazao JM; Goodkin DA; Turner SA; Liu W; Coburn JW
    Kidney Int; 2000 Jul; 58(1):436-45. PubMed ID: 10886592
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Combined therapy with calcitonin and high doses of active vitamin D3 metabolites in uremic hyperparathyroidism].
    Matuszkiewicz-Rowińska J; Niemczyk S; Puka J; Sawicki A; Switalski M; Tałałaj M; Pacocha E; Marusza W; Ostrowski K
    Pol Arch Med Wewn; 1996 Jul; 96(1):23-31. PubMed ID: 8966142
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.